Bibliography
- Wolf R, Wolf D, Davidovici B. In the pursuit of classifying severe cutaneous adverse reactions. Clin Dermatol 2007;25:438-9
- Lissia M, Mulas P, Bulla A, Toxic epidermal necrolysis (Lyell's disease). Burns 2010;36:152-63
- Paquet P, Pierard GE. New insights in toxic epidermal necrolysis (Lyell's syndrome). Clinical considerations, pathobiology and targeted treatments revisited. Drug Saf 2010;33:189-212
- Mockenhaupt M, Viboud C, Dunant A, Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008;128:35-44
- Stone N, Sheerin S, Burge S. Toxic epidermal necrolysis and graft vs host disease: a clinical spectrum but a diagnostic dilemma. Clin Exp Dermatol 1999;24:260-2
- Paquet P, Arrese JE, Beguin Y, Clinicopathological differential diagnosis of drug-induced toxic epidermal necrolysis (Lyell's syndrome) and acute graft-versus-host reaction. Curr Top Pathol 2001;94:49-63
- Chung WH, Hung Si, Hong HS, Medical genetics: a marker for Stevens–Johnson syndrome. Nature 2004;428:486
- Paquet P, Pierard GE. Toxic epidermal necrolysis: revisiting the tentative link between early apoptosis and late necrosis. Int J Mol Med 2007;19:3-10
- Paquet P, Nikkels A, Arrese J, Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol 1994;130:605-8
- Viard I, Wehrli P, Bullani R, Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-3
- Paquet P, Pierard GE. Epidermal calprotectin in drug-induced toxic epidermal necrolysis. J Cutan Pathol 1999;26:301-5
- Paquet P, Pierard GE. Glutathione-S-transferase phi expression in toxic epidermal necrolysis: a marker of putative oxidative stress in keratinocytes. Skin Pharmacol Physiol 2007;20:66-70
- Nassif A, Bensussan A, Bournsell L, Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004;114:1209-15
- Paquet P, Jacob E, Damas P, Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis. Arch Dermatol Res 2005;297:266-73
- Chung WH, Hung SI, Yang JY, Granulysin is a key mediator for disseminated keratinocyte death in Stevens–Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008;14:1343-50
- Paquet P, De Groote D, Pierard GE. Functionally-active macrophage-derived myeloperoxidase in the skin of drug-induced toxic epidermal necrolysis. Dermatology 2010;220:201-7
- Paquet P, Pierard GE, Quatresooz P. Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome). Int Arch Allergy Immunol 2005;136:205-16
- Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002;146:707-8
- Famularo G, Di Dona B, Canzona F, Etanercept for toxic epidermal necrolysis. Ann Pharmacother 2007;41:1083-4
- Paquet P, Pierard GE. Topical treatment options for drug-induced toxic epidermal necrolysis (TEN). Expert Opin Pharmacother 2010;11:2447-58